CONTEXT: 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy) pyridine (2-F-A-85380, abbreviated as 2-FA) is a recently developed radioligand that allows for visualization of brain alpha 4 beta 2* nicotinic acetylcholine receptors (nAChRs) with positron emission tomography (PET) scanning in humans. OBJECTIVE: To determine the effect of cigarette smoking on alpha 4 beta 2* nAChR occupancy in tobacco-dependent smokers. DESIGN: Fourteen 2-FA PET scanning sessions were performed. During the PET scanning sessions, subjects smoked 1 of 5 amounts (none, 1 puff, 3 puffs, 1 full cigarette, or to satiety [2(1/2) to 3 cigarettes]). SETTING: Academic brain imaging center. PARTICIPANTS: Eleven tobacco-dependent smokers (paid volunteers). Main Outcome Measure Dose-dependent effect of smoking on occupancy of alpha 4 beta 2* nAChRs, as measured with 2-FA and PET in nAChR-rich brain regions. RESULTS: Smoking 0.13 (1 to 2 puffs) of a cigarette resulted in 50% occupancy of alpha 4 beta 2* nAChRs for 3.1 hours after smoking. Smoking a full cigarette (or more) resulted in more than 88% receptor occupancy and was accompanied by a reduction in cigarette craving. A venous plasma nicotine concentration of 0.87 ng/mL (roughly 1/25th of the level achieved in typical daily smokers) was associated with 50% occupancy of alpha 4 beta 2* nAChRs. CONCLUSIONS: Cigarette smoking in amounts used by typical daily smokers leads to nearly complete occupancy of alpha 4 beta 2* nAChRs, indicating that tobacco-dependent smokers maintain alpha 4 beta 2* nAChR saturation throughout the day. Because prolonged binding of nicotine to alpha 4 beta 2* nAChRs is associated with desensitization of these receptors, the extent of receptor occupancy found herein suggests that smoking may lead to withdrawal alleviation by maintaining nAChRs in the desensitized state.
CONTEXT: 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy) pyridine (2-F-A-85380, abbreviated as 2-FA) is a recently developed radioligand that allows for visualization of brain alpha 4 beta 2* nicotinic acetylcholine receptors (nAChRs) with positron emission tomography (PET) scanning in humans. OBJECTIVE: To determine the effect of cigarette smoking on alpha 4 beta 2* nAChR occupancy in tobacco-dependent smokers. DESIGN: Fourteen 2-FA PET scanning sessions were performed. During the PET scanning sessions, subjects smoked 1 of 5 amounts (none, 1 puff, 3 puffs, 1 full cigarette, or to satiety [2(1/2) to 3 cigarettes]). SETTING: Academic brain imaging center. PARTICIPANTS: Eleven tobacco-dependent smokers (paid volunteers). Main Outcome Measure Dose-dependent effect of smoking on occupancy of alpha 4 beta 2* nAChRs, as measured with 2-FA and PET in nAChR-rich brain regions. RESULTS: Smoking 0.13 (1 to 2 puffs) of a cigarette resulted in 50% occupancy of alpha 4 beta 2* nAChRs for 3.1 hours after smoking. Smoking a full cigarette (or more) resulted in more than 88% receptor occupancy and was accompanied by a reduction in cigarette craving. A venous plasma nicotine concentration of 0.87 ng/mL (roughly 1/25th of the level achieved in typical daily smokers) was associated with 50% occupancy of alpha 4 beta 2* nAChRs. CONCLUSIONS: Cigarette smoking in amounts used by typical daily smokers leads to nearly complete occupancy of alpha 4 beta 2* nAChRs, indicating that tobacco-dependent smokers maintain alpha 4 beta 2* nAChR saturation throughout the day. Because prolonged binding of nicotine to alpha 4 beta 2* nAChRs is associated with desensitization of these receptors, the extent of receptor occupancy found herein suggests that smoking may lead to withdrawal alleviation by maintaining nAChRs in the desensitized state.
Authors: Adrianna Mendrek; John Monterosso; Sara L Simon; Murray Jarvik; Arthur Brody; Richard Olmstead; Catherine P Domier; Mark S Cohen; Monique Ernst; Edythe D London Journal: Addict Behav Date: 2005-07-11 Impact factor: 3.913
Authors: Sascha Mitkovski; Victor L Villemagne; Kathy E Novakovic; Graeme O'Keefe; Henri Tochon-Danguy; Rachel S Mulligan; Kerryn L Dickinson; Tim Saunder; Marie-Claude Gregoire; Michel Bottlaender; Frederic Dolle; Christopher C Rowe Journal: Nucl Med Biol Date: 2005-08 Impact factor: 2.408
Authors: Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady Journal: Mol Pharmacol Date: 2004-06 Impact factor: 4.436
Authors: James Robert Brašić; Nicola Cascella; Anil Kumar; Yun Zhou; John Hilton; Vanessa Raymont; Andrew Crabb; Maria Rita Guevara; Andrew G Horti; Dean Foster Wong Journal: Synapse Date: 2011-12-29 Impact factor: 2.562
Authors: Amir H Rezvani; Susan Slade; Cori Wells; Ann Petro; Lawrence Lumeng; Ting-Kai Li; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Jed E Rose; Kenneth J Kellar; Edward D Levin Journal: Psychopharmacology (Berl) Date: 2010-06-10 Impact factor: 4.530
Authors: Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman Journal: J Nucl Med Date: 2015-08-13 Impact factor: 10.057